Q1 Earnings Estimate for DYN Issued By HC Wainwright

Dyne Therapeutics, Inc. (NASDAQ:DYN) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Dyne Therapeutics in a research note issued on Friday, February 28th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.90) for the quarter. HC Wainwright currently has a “Buy” rating and a $46.00 price objective on the stock. The consensus estimate for Dyne Therapeutics’ current full-year earnings is ($3.44) per share. HC Wainwright also issued estimates for Dyne Therapeutics’ Q2 2025 earnings at ($0.91) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.91) EPS and FY2029 earnings at $1.56 EPS.

DYN has been the subject of several other reports. Guggenheim restated a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Robert W. Baird began coverage on Dyne Therapeutics in a research note on Friday, December 13th. They set an “outperform” rating and a $46.00 price objective for the company. Piper Sandler decreased their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Royal Bank of Canada reissued an “outperform” rating and set a $45.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, January 14th. Finally, Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $48.64.

Dyne Therapeutics Trading Down 3.5 %

Shares of NASDAQ:DYN opened at $11.89 on Monday. The stock has a market capitalization of $1.21 billion, a P/E ratio of -3.34 and a beta of 1.11. The stock’s 50-day moving average price is $16.75 and its 200-day moving average price is $27.26. Dyne Therapeutics has a 12-month low of $11.62 and a 12-month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, March 4th. The company reported ($0.88) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04.

Insider Activity

In other Dyne Therapeutics news, insider Oxana Beskrovnaya sold 2,334 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total transaction of $65,632.08. Following the transaction, the insider now owns 201,685 shares in the company, valued at approximately $5,671,382.20. This represents a 1.14 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Richard William Scalzo sold 1,455 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the sale, the senior vice president now owns 127,078 shares in the company, valued at $3,573,433.36. This represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,387 shares of company stock valued at $142,789. Corporate insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Quantbot Technologies LP purchased a new position in Dyne Therapeutics during the 3rd quarter valued at about $34,000. Point72 DIFC Ltd bought a new position in shares of Dyne Therapeutics during the third quarter valued at approximately $36,000. US Bancorp DE lifted its holdings in shares of Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares during the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Dyne Therapeutics in the 4th quarter worth approximately $50,000. Finally, KBC Group NV grew its stake in shares of Dyne Therapeutics by 45.3% in the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after buying an additional 978 shares during the last quarter. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.